Cost‐Effectiveness of Icosapent Ethyl in REDUCE‐IT USA: Results From Patients Randomized in the United States

Background In 3146 REDUCE‐IT USA (Reduction of Cardiovascular Events With Icosapent Ethyl Intervention Trial USA) participants, icosapent ethyl (IPE) reduced first and total cardiovascular events by 31% and 36%, respectively, over 4.9 years of follow‐up. Methods and Results We used participant‐level...

詳細記述

書誌詳細

出版年:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
主要な著者:	William S. Weintraub, Deepak L. Bhatt, Zugui Zhang, Sarahfaye Dolman, William E. Boden, Adam P. Bress, Brandon K. Bellows, Catherine G. Derington, Sephy Philip, Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Jean‐Claude Tardif, Christie M. Ballantyne, Paul Kolm
フォーマット:	論文
言語:	英語
出版事項:	Wiley 2024-01-01
主題:	cardiovascular prevention cost‐effectiveness hyperlipidemia
オンライン･アクセス:	https://www.ahajournals.org/doi/10.1161/JAHA.123.032413